MedTrace Logo

Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)

NCT00517309 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1877

Last updated 2017-03-22

No results posted yet for this study

Summary

The primary purpose of the study is to test the safety of HPV Vaccine in Women

Conditions

Interventions

BIOLOGICAL

V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years

BIOLOGICAL

Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
23 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-12-28
Primary Completion
2004-06-08
Completion
2004-06-11

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00517309 on ClinicalTrials.gov